In short
This article discusses a clinical trial investigating the use of a drug containing Allergenic Extract of Juniperus Oxycedrus Pollen Polymerized with Glutaraldehyde, along with other grass pollen extracts, for treating allergic rhinitis and rhinoconjunctivitis. The study aims to assess the effectiveness and safety of this subcutaneous immunotherapy in patients with moderate to severe allergic symptoms, with or without mild asthma.
At a glance
- Study Type
- Phase III clinical trial: Prospective, multicentre, randomized, double-blind, placebo-controlled
- Main Objective
- Evaluate clinical efficacy of subcutaneous polymerized allergen extracts vs placebo
- Target Population
- Patients aged 12-65 with moderate-severe allergic rhinitis/rhinoconjunctivitis, with/without mild-moderate asthma
- Investigational Drug
- Mixture of modified allergen extracts from 6 grasses and Juniperus oxycedrus pollen
- Administration
- Subcutaneous injection, max daily dose 0.5 ml
- Treatment Duration
- Up to 12 months
- Primary Outcome
- Overall symptom and medication score during pollen season
- Key Secondary Outcomes
- Symptom-free days, medication-free days, asthma exacerbations, quality of life
What is ALLERGENIC EXTRACT OF JUNIPERUS OXYCEDRUS POLLEN POLYMERIZED WITH GLUTARALDEHYDE?
ALLERGENIC EXTRACT OF JUNIPERUS OXYCEDRUS POLLEN POLYMERIZED WITH GLUTARALDEHYDE is a specialized medication used in allergen immunotherapy. It is derived from the pollen of Juniperus oxycedrus, also known as the prickly juniper or cade juniper. This extract is chemically modified (polymerized) using glutaraldehyde to enhance its effectiveness and safety profile.
This medication is part of a larger group of treatments called allergen extracts, which are used to desensitize the immune system to specific allergens. In this case, the treatment targets allergies related to Juniperus oxycedrus pollen.
Medical Conditions Treated
This medication is primarily used to treat:
- Allergic rhinitis: An inflammation of the nasal passages caused by an allergic reaction, resulting in symptoms like sneezing, runny nose, and nasal congestion.
- Allergic rhinoconjunctivitis: A condition that affects both the nose and eyes, causing symptoms in both areas due to an allergic reaction.
- Mild to moderate allergic asthma: A type of asthma triggered by allergens, in this case, specifically related to Juniperus oxycedrus pollen.
The treatment is particularly focused on individuals with moderate to severe intermittent or persistent forms of these conditions.
How It Works
This medication works through a process called immunotherapy. Here's a simplified explanation of how it functions:
- The allergenic extract contains small amounts of the allergen (Juniperus oxycedrus pollen).
- When administered to patients, it gradually exposes their immune system to the allergen.
- Over time, this exposure helps the immune system become less sensitive to the allergen.
- As a result, when the person encounters the allergen in their environment, their allergic reactions become less severe or may even stop altogether.
Current Clinical Trial
A clinical trial is currently underway to evaluate the effectiveness and safety of this treatment. The trial is described as a "Prospective, multicentre, randomized, double-blind, placebo-controlled, clinical trial".
Key aspects of the trial include:
- It's a Phase III clinical trial, which means it's in an advanced stage of testing.
- The treatment is being administered subcutaneously (under the skin).
- It's comparing the active treatment to a placebo to determine its effectiveness.
- The trial is focusing on patients with rhinitis/rhinoconjunctivitis, with or without mild to moderate asthma.
Eligibility Criteria
The trial has specific criteria for who can participate. Some key inclusion criteria are:
- Ages 12 to 65 years
- Confirmed history of allergy to grass and cupressaceae (cypress family) pollen
- Positive skin prick test to the allergens
- Specific IgE levels above 3.5 KU/L for the allergens
There are also several exclusion criteria, such as severe asthma, certain other medical conditions, and recent immunotherapy treatments.
Administration and Dosage
The medication is administered as a suspension for injection, given subcutaneously (under the skin). The maximum daily dose is 0.5 ml, with a maximum treatment period of 12 months.
Potential Benefits
The clinical trial aims to assess several potential benefits, including:
- Reduction in overall symptoms and medication use during pollen seasons
- Increase in symptom-free and medication-free days
- Improvement in quality of life
- Better control of asthma symptoms
- Changes in immunological parameters (IgE and IgG4 levels)
Safety Considerations
As with any medical treatment, there are potential risks and safety considerations:
- The trial is closely monitoring for any adverse events, including local reactions at the injection site and systemic reactions.
- Certain individuals, such as those with severe asthma, other significant health conditions, or pregnancy, are excluded from the trial due to potential risks.
- The treatment is not recommended for individuals with certain autoimmune diseases, cancer, or immunodeficiencies.
It's important to note that this treatment should only be administered under the supervision of a qualified healthcare professional, as they can properly assess individual risks and benefits.